MedTrace Logo

GCWB1176 Evaluates the Effectiveness and Safety of Immune Function

NCT05632341 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-23

No results posted yet for this study

Summary

This human application test was planned to evaluate the effectiveness and safety of immunodefinition compared to the placebo when the GCWB1176 was consumed for those whose white blood cell level was normal or somewhat decreased.

Conditions

  • Immune Function

Interventions

DIETARY_SUPPLEMENT

Lactococcus lactis

1 capsule once a day

OTHER

maltodextrin

1 capsule once a day

Sponsors & Collaborators

  • Green Cross Wellbeing

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2024-01-31
Completion
2024-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05632341 on ClinicalTrials.gov